Halozyme Therapeutics Stock Guidance | NASDAQ:HALO | Benzinga

Halozyme Therapeutics issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.

											Get Alert
11/03/2025	HALO	Halozyme Therapeutics	FY	2025	$6.10	$6.50	$5.46	$1.30B	$1.38B	$1.32B	Get Alert
10/01/2025	HALO	Halozyme Therapeutics	FY	2025	$6.00	$6.40	$5.97	$1.27B	$1.35B	$1.32B	Get Alert
08/05/2025	HALO	Halozyme Therapeutics	FY	2025	$6.00	$6.40	$5.31	$1.27B	$1.35B	$1.25B	Get Alert
05/06/2025	HALO	Halozyme Therapeutics	FY	2025	$5.30	$5.70	$5.00	$1.20B	$1.28B	$1.19B	Get Alert
02/18/2025	HALO	Halozyme Therapeutics	FY	2025	$4.95	$5.35	$5.05	$1.15B	$1.23B	$1.18B	Get Alert
01/08/2025	HALO	Halozyme Therapeutics	FY	2024	$4.00	$4.20	$4.14	$970.00M	$1.02B	$1.00B	Get Alert
01/08/2025	HALO	Halozyme Therapeutics	FY	2025	$4.95	$5.35	$4.69	$1.15B	$1.23B	$1.16B	Get Alert
10/31/2024	HALO	Halozyme Therapeutics	FY	2024	$4.00	$4.20	$3.96	$970.00M	$1.02B	$983.85M	Get Alert
08/06/2024	HALO	Halozyme Therapeutics	FY	2024	$3.65	$4.05	$3.99	$935.00M	$1.01B	$989.87M	Get Alert
06/06/2024	HALO	Halozyme Therapeutics	FY	2024	$3.65	$4.05	$3.73	$935.00M	$1.01B	$947.33M	Get Alert
05/07/2024	HALO	Halozyme Therapeutics	FY	2024	$3.55	$3.90	$3.68	$915.00M	$985.00M	$951.47M	Get Alert
02/20/2024	HALO	Halozyme Therapeutics	FY	2024	$3.55	$3.90	$3.51	$915.00M	$985.00M	$961.09M	Get Alert
01/17/2024	HALO	Halozyme Therapeutics	FY	2023	$2.77	$2.80	$2.74	$827.00M	$832.00M	$835.69M	Get Alert
11/06/2023	HALO	Halozyme Therapeutics	FY	2023	$2.70	$2.80	$2.65	$825.00M	$845.00M	$835.91M	Get Alert
08/08/2023	HALO	Halozyme Therapeutics	FY	2023	$2.65	$2.75	$2.61	$825.00M	$845.00M	$823.06M	Get Alert
05/09/2023	HALO	Halozyme Therapeutics	FY	2023	$2.50	$2.65	$2.57	$815.00M	$845.00M	$833.00M	Get Alert
03/15/2023	HALO	Halozyme Therapeutics	FY	2023	—	—	—	$815.00M	$845.00M	$829.01M	Get Alert
02/21/2023	HALO	Halozyme Therapeutics	FY	2023	$2.50	$2.65	$2.78	$815.00M	$845.00M	$868.12M	Get Alert
01/10/2023	HALO	Halozyme Therapeutics	FY	2023	$2.50	$2.65	$2.90	$815.00M	$845.00M	$892.47M	Get Alert
11/08/2022	HALO	Halozyme Therapeutics	FY	2022	$2.10	$2.25	$2.04	$655.00M	$685.00M	$661.33M	Get Alert
08/09/2022	HALO	Halozyme Therapeutics	FY	2022	$2.10	$2.25	$2.23	$655.00M	$685.00M	$610.87M	Get Alert
05/10/2022	HALO	Halozyme Therapeutics	FY	2022	$2.05	$2.20	$2.23	$530.00M	$560.00M	$566.18M	Get Alert
04/13/2022	HALO	Halozyme Therapeutics	FY	2022	$2.05	$2.20	$2.18	$530.00M	$560.00M	$553.27M	Get Alert
02/22/2022	HALO	Halozyme Therapeutics	FY	2022	$2.05	$2.20	$2.18	$530.00M	$560.00M	$554.20M	Get Alert
01/10/2022	HALO	Halozyme Therapeutics	FY	2022	$2.05	$2.20	$2.68	$530.00M	$560.00M	$569.39M	Get Alert

FAQ

What is the most recent guidance for Halozyme Therapeutics (HALO)?

The most recent guidance for Halozyme Therapeutics (HALO) was reported on November 3, 2025 for the full year 2025. The company provided earnings per share guidance in the range of $6.10 to $6.50, compared to the estimated EPS of $5.46. Additionally, Halozyme Therapeutics forecasted revenue between $1.30B and $1.38B for the quarter.

Browse guidance and forecast on all stocks.